Atlas Trials

Accent Therapeutics

2 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Accent Therapeutics

RecordFirmDate
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer (NCT06799065)Accent Therapeutics2025-03-21
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers (NCT06625515)Accent Therapeutics2024-10-11

Track Accent Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.